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Meyer, 2003). The mechanisms of resistance to amino-Can Mosquitoes Be Bitten? A New
alcohol-based drugs are still unclear.Hope for Anti-Malarial Drug Design The development of resistance is correlated to the
half-life of a drug such that resistance evolves more
rapidly against drugs with a long (on the scale of days
to weeks) half-life (Hastings et al., 2002). The tendency
The crystal structure of PfPK5, a cyclin-dependent ki- for development of resistance is higher with lower kill-
nase from Plasmodium falciparum, is the first CDK rate drugs because the percentage of surviving para-
structure determined from a nonhuman source and sites is higher at a given drug concentration. While only
represents a potential new target for anti-malarial drug 4 of the nearly 1400 new drugs registered worldwide in
development. the last quarter of the twentieth century were anti-malar-
ial therapies (Trouiller et al., 2002), increased resistance
Malaria, particularly the most virulent strain caused by to existing drugs has caused a resurgence in the effort
the protozoan parasite Plasmodium falciparum, is one to develop new compounds for the treatment of malaria.
of the most devastating diseases worldwide. The single- Novel and innovative artemisinin and derivative com-
celled parasite is transmitted from person to person pounds have been discovered in China, but their general
through the bite of an infected female Anopheles mos- availability is limited because their developments do not
quito, which must draw blood meals from unsuspecting meet international criteria (Olliaro and Taylor, 2003).
hosts in order to nurture her eggs. According to the The best candidates for effective therapies are drugs
World Health Organization (www.rbm.who.int), approxi- that quickly reach high levels in plasma and kill all para-
mately 40% of the world’s population, most of whom sites before gametocytogeny and are then immediately
live in the world’s poorest nations, are at risk of malaria eliminated (May and Meyer, 2003). Toward that goal, a
infection, with 300–500 million people infected annually. strong case has been made for the use of combination
There are 1–3 million deaths worldwide due to malaria therapies in the routine treatment of malaria. Although
each year, 90% of them in sub-Saharan Africa, where combination therapy increases the cost as well as the
children and pregnant women are at the highest risk. complexity of treatment, combination therapy has dem-
Malaria kills an African child approximately every 30 onstrated clear advantages in efficacy and in decreased
seconds and is the leading cause of mortality for chil- selection of resistant strains in other infectious diseases
dren under the age of 10. including tuberculosis and AIDS. Most anti-malarial
Records supporting attempts to control malaria through combination therapies have focused on the use of arte-
the use of mass treatment with anti-malarial drugs date sunate combined with either quinoline or antifolate
back to 1932, with the drug plasmoquine (von Seidlein drugs (Olliaro and Taylor 2003), but the use of falcipain
and Greenwood, 2003). Throughout the twentieth cen- (cysteine protease) inhibitors in combination with other
tury, quinoline and antifolate type chemotherapies— synergistic agents such as aspartic protease inhibitors
drugs that are readily accessible as well as most af- has also been proposed (Semenov et al., 1998). Cysteine
fordable—have been most commonly used and, for protease inhibitors have been shown to block the hydro-
periods of time, showed significant efficacy. However, lysis of hemoglobin by erythrocytic parasites, causing
resistance has curtailed the effective lifespan of these the parasite’s food vacuole to fill with undegraded he-
and all first line anti-malarials. The mechanisms of resis- moglobin. Subsequently, parasite development is pre-
tance in P. falciparum malaria are becoming better under- vented.
stood and have their origins in chromosomal mutations. In the current issue of Structure, a new potential target
Chloroquine, which—in nonresistant parasites—becomes for antimalarial chemotherapeutics is detailed (Holton
concentrated in the digestive vacuole of the intraer- et al., 2003). The structure of PfPK5, the first structure
ythrocytic trophozoite form of P. falciparum, forms a of a cyclin-dependent kinase from a nonhuman source
complex with heme and inhibits heme detoxification. is reported. Protein kinases have become a prominent
Chloroquine resistant organisms, however, display a target for therapeutic development against major human
lack of accumulation of chloroquine and allow for the diseases in the Western hemisphere, including cancer,
normal degradation of hemoglobin by the parasite. This inflammation and rheumatoid arthritis, diabetes, neuro-
phenotype is correlated with mutations of the Pfmdf1, logical dysfunction, and cardiovascular disease. Con-
Pfcg2, and Pfcrt genes (Le Bras and Durand, 2003). trary to fears that selectivity could not be achieved
Resistance to the antifolates stems from one to four point amongst the myriad proteins that utilize ATP, kinase-
mutations in the sequence of dihydrofolate reductase directed drug development is now a clinical reality.
(DHFR), the target enzyme for these drugs. In addition, Drugs have been approved for market and others are
resistance to the sulfonamide and sulfone drugs stems in late-stage clinical trials. All of these demonstrate se-
from inhibition of dihydropteroate synthase (DHPS), an- lectivity profiles that target a discrete class of kinases
other target enzyme involved in dihydrofolate synthesis. without crossreacting with other kinases that would en-
Characterization of the pfdhps and pfdhfr genes sug- gender significant side effects (such as IRK). One promi-
gests that mutations in their sequences are implicated nent example, the FDA-approved drug Gleevec (imatinib
mesylate, STU-571), is a potent inhibitor of the constitu-in this resistance (Le Bras and Durand, 2003; May and
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ously forming a 5 phosphate linkage to a conservedA Mob of Reps
active site tyrosine and liberating the 3 OH adjacent to
the nick site. During subsequent elongation, the protein
that made the nick stays covalently attached to the pa-
rental strand. When the newly synthesized strand com-
pletes one round of replication it reaches the originalEmerging structural results confirm that the large Roll-
site of nicking. At that point another tyrosine proximaling Circle Replication initiator superfamily is com-
to the first attaches to the DNA and the system is readyposed of two classes of proteins that are circularly
for another round of replication around the plasmid (vanpermutated with respect to each other, as initially sug-
Mansfeld et al., 1986).gested by sequence analysis. The two classes are
The entire superfamily is characterized by two se-united by the same endonucleolytic mechanism and
quence motifs: an HUH motif, or motif 2, (where U is aa conserved Mg2 binding site containing multiple his-
hydrophobic residue) presumed to ligate a Mg2 iontidine ligands unique to this superfamily.
required for the nicking activity, and a YxxxY motif, or
motif 3, the tyrosines that attach covalently to the DNA.
It has now been over 10 years since Ilyina and Koonin Ilyina and Koonin showed that the superfamily extends
(1992) pointed out the existence of a vast superfamily far beyond the RCR proteins of coliphages, and includes
spanning eubacteria, archea, and eucarya tied together replication initiators of various eubacterial plasmids,
by sequence signatures found originally in domains of ssDNA viruses infecting Spiroplasma and Chlamydia,
proteins involved in the initiation and termination of roll- plant geminiviruses, and mammalian parvoviruses.
ing circle replication (RCR). RCR, as prototyped by the While these are not all bone fide RCR domains, as some
ssDNA coliphageφX174, involves the site-specific nick- lack one of the tyrosines of the YxxxY motif, they all
share the HUH motif and a conserved tyrosine and,ing of a plasmid strand by the RCR protein, simultane-
